RecruitingPhase 3NCT06123156

Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer

Intérêt de la rééducation érectile précoce Par Sildénafil après radiothérapie et Proctectomie Pour Cancer du Rectum : Essai contrôlé randomisé


Sponsor

University Hospital, Rouen

Enrollment

188 participants

Start Date

Sep 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to evaluate the efficacy of erectile rehabilitation with Sildenafil, in men treated with neoadjuvant proctectomy and radiotherapy for rectal cancer, in preventing long-term erectile dysfunction at 12 months post-operatively.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 70 Years

Inclusion Criteria7

  • Men aged 18 to 70
  • Patients undergoing surgery for cancer of the lower or middle rectum by total removal of the mesorectum with colorectal or coloanal anastomosis after neoadjuvant radiotherapy, with normal preoperative erectile function (defined by a combined IIEF erectile function domain score of at least 22).
  • Nerve-conserving surgery
  • Sexually active patient without treatment for erectile function prior to surgery
  • Presence of a regular sexual partner (male or female)
  • Adult having read and understood the information letter and signed the consent form
  • Membership of a social security scheme

Exclusion Criteria11

  • T4 tumor or tumor requiring extended surgery
  • Patients with abnormal erectile function defined by a combined IIEF erectile function domain score of less than 22.
  • History of prostate cancer
  • Sleep disorders, patients taking sedatives/hypnotics
  • Contraindication to SILDENAFIL EG 50 mg, film-coated tablet
  • Contraindication to placebo
  • Patients already treated with PDE5 inhibitors
  • Patients suffering from SARS COV 2*
  • Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship.
  • Any history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol, or to prevent the subject from giving informed consent.
  • Person participating in another drug trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSildenafil

Sildénafil during 10 months (50mg daily), start 30 days after surgery

OTHERPlacebo

1 platelet during 10 months (daily), start 30 days after surgery


Locations(14)

Chu Amiens

Amiens, France

Hopital Beauvais

Beauvais, France

Chu Besancon

Besançon, France

Aphp Bicetre

Bicêtre, France

Chu Bordeaux

Bordeaux, France

Institut Bordeaux Colorectal

Bordeaux, France

Chu Clermont-Ferrand

Clermont-Ferrand, France

Chu Lille

Lille, France

Institut Paoli-Calmettes

Marseille, France

Institut Du Cancer Montpellier

Montpellier, France

Aphp St Antoine

Paris, France

Aphp Hegp

Paris, France

Chu Rouen

Rouen, France

Chu Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06123156


Related Trials